ERBB2 and breast carcinoma: The HER2+ subtype occurs in 20% of breast cancers and is sensitive to HER2-based-targeted therapies such as the humanized, monoclonal antibody trastuzumab, or the small molecule tyrosine kinase inhibitor, lapatinib.